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Abstract
Background: Focal 68Ga-DOTATATE PET lesions within the myocardium of neuroendocrine tumor (NET) patients
are observed in clinical practice. We determined the frequency and characteristics of lesions that are consistent
with cardiac metastasis and assessed the lesion detection rate of conventional imaging.
Methods: 629 patients who underwent 68Ga-DOTATATE PET-CT at a supraregional comprehensive cancer center
on NET were included from a consecutive registry. Inclusion criteria were: (1) focal 68Ga-DOTATATE tracer uptake
within the myocardium in more than two sequential PET exams, and (2) contrast-enhanced CT. To determine the
diagnostic accuracy of conventional CT imaging, a case-control cohort with a ratio of 1:3 was used. PET and CT
were independently analyzed by two blinded readers. Cohen’s κ was assessed for interreader agreement.
Descriptive statistics were applied for frequencies and characteristics and group comparisons were analyzed using
the Fisher’s exact test.
Results: The prevalence of myocardial metastases related to the registry was 2.4% (15 of 629 NET patients fulfilling
the inclusion criteria), for a total of 21 myocardial 68Ga-DOTATATE foci detected. Myocardial lesions were most
frequently located in the left ventricle (43%) and the septum (43%). No patient demonstrated a pericardial effusion.
Patients with myocardial metastases did not differ in demographics, tumor grading, disease stage or circulating
tumor markers compared to the overall registry (all p > 0.05). Higher Ki67-Indices were observed (p = 0.049) for
patients with myocardial metastases. Interreader agreement for PET assessment was excellent (Cohen’s κ = 1.0).
CT reading showed a sensitivity of 19% (95% confidence interval: 6–43%) at a specificity of 100% (95% confidence
interval: 90–100%).
Conclusions: 68Ga-DOTATATE PET enables detection of myocardial metastatic lesions in NET patients. In contrast,
standard morphologic CT imaging provides very limited sensitivity.
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Background
Neuroendocrine tumors (NET) represent a heteroge-
neous entity of malignant neoplasms that arise from the
cells of the endocrine system [1–3]. At initial staging as
well as in therapy monitoring, the use of positron emis-
sion tomography (PET) has prevailed over conventional
imaging assessment due to a significantly higher sensitiv-
ity and specificity [4]. In particular for NET, the tracer
68Ga-DOTATATE allows the detection of metastases
based on the typical expression of somatostatin receptor
2 (SSTR2) in well-differentiated NET [5].
The heart is a rare but important site of metastasis for
many malignant tumors, which can be localized in differ-
ent cardiac spaces including the myocardium and pericar-
dium [6, 7]. Pericardial metastases often manifest with
concomitant pericardial effusion, which facilitates their
diagnosis in conventional computed tomography (CT) or
magnetic resonance imaging (MRI). Myocardial metasta-
ses, however, often remain undetected until autopsy as
indicated by the large differences in the frequency of myo-
cardial metastases in autopsies compared to conventional
oncologic imaging [7]. Yet, a reliable way of detecting
myocardial metastases is of clinical relevance as it may in-
fluence treatment decisions [8, 9].
CT as the most frequently used modality in oncologic
imaging has limited sensitivity for the detection of
myocardial metastases compared to MRI [7]. Moreover,
the most frequently applied PET tracer [18F]-fluorodeoxy-
glucose (18F-FDG) in oncologic imaging shows high
physiologic uptake in the myocardium, which masks focal
myocardial lesions with altered glucose metabolism. In
contrast to 18F-FDG, the tracer 68Ga-DOTATATE only
shows a non-specific background-level uptake of the myo-
cardium [10].
We hypothesize that focal myocardial 68Ga-DOTATA
TE tracer uptake may contribute to the detection of
myocardial metastases in patients with NET. We sought
to characterize prevalence, clinical and imaging char-
acteristics in these patients based on the registry of a
supraregional interdisciplinary comprehensive cancer
center on NET.
Methods
Study design and population
The institutional review board of the LMU Munich
(Ethikkommission der Medizinischen Fakultät der
Ludwig-Maximilians-Universität München) approved
this retrospective study, which was conducted according
to the Helsinki Declaration of 2013, and waived require-
ment for informed consent. Based on a prospectively
collected NET patient registry at the Interdisciplinary
Center for Neuroendocrine Tumors of the Gastroenter-
opancreatic System (GEPNET-KUM), our initial cohort
consisted of 629 consecutive patients who underwent
68Ga-DOTATATE PET-CT between March 2012 and
March 2017.
Out of this cohort, we included all subjects with
(1) focal myocardial 68Ga-DOTATATE tracer uptake
in at least two sequential PET exams, and
(2) contrast-enhanced CT.
We excluded patients with
(1) non-enhanced CT, and
(2) non-diagnostic quality of PET or CT.
PET-CT and MRI examination protocol
All patients underwent 68Ga-DOTATATE PET-CT (Bio-
graph 64; Siemens Healthcare) 60 min after intravenous
injection of a median 223 MBq (standard deviation
22 MBq) of 68Ga-DOTATATE. First, contrast-enhanced
CT scans (1.5 mL of iopromide [Ultravist-300; Bayer
Healthcare] per kilogram of body weight) were obtained
for anatomic localization. Subsequently, the PET scan was
acquired by static emission data for 3 min per bed pos-
ition. PET images were reconstructed using an iterative
algorithm (ordered-subset expectation maximization: 4 it-
erations, 8 subsets). Contrast-enhanced CT data were re-
constructed with a slice thickness of 2.0 mm (axial). The
reconstructed PET, CT, and fused images were analyzed
on the manufacturer’s imaging software (syngo.via; Sie-
mens Healthcare; Forchheim, Germany). Liver MRI,
which was routinely performed on 1.5- or 3.0-T scanners
(MAGNETOM Aera, MAGNETOM Avanto; Siemens
Healthcare; Forchheim, Germany) as a part of the comple-
mentary NET staging for the detection of liver metastases,
was used to crosscheck for possible heart metastases in
cases when the heart or parts of it were included in the
field of view. The standard liver MRI imaging protocol
consisted of T1-w fast spin echo (FSE) sequences in- and
opposed phase, a T2-weighted single-shot FSE sequence
without fat saturation (fs), and a breath-hold T2-weighted
FSE sequence with fs. We intravenously administrated the
contrast agent Gd-EOB-DTPA (Primovist; Bayer Health-
care; Leverkusen, Germany) (0.1 mL of a 0.25 mmol/mL
solution per kilogram of body weight) and used a dynamic
T1-weighted gradient echo sequence (volumetric interpo-
lated breath-hold examination [VIBE]) with fs. This proto-
col was not optimized for cardiac imaging. Only 5 patients
underwent an additional dedicated cardiac MRI protocol.
Definition of myocardial metastasis on 68Ga-DOTATATE
PET and prevalence
Focal 68Ga-DOTATATE tracer uptake was considered
consistent with myocardial metastasis when clearly lo-
cated in the myocardium and if the uptake was evident on
at least two sequential PET exams. Due to the missing
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necessity for a myocardial biopsy in the overall manage-
ment of metastasized NET patients, histopathological
validation of the myocardial lesions was not available. In a
subgroup of five patients, the myocardial lesions could
be confirmed by the use of dedicated cardiac MRI ex-
aminations. The prevalence of myocardial lesions on
68Ga-DOTATATE PET in NET patients was calculated
in relation to the total number of patients treated at
our institution in the given time period of this study.
Diagnostic accuracy of CT for myocardial lesions on 68Ga-
DOTATATE PET
To determine the diagnostic accuracy of conventional
CT imaging, a case-control-cohort with a ratio of 1:3
was set up including patients without focal myocardial
uptake as controls. This design also allows to determine
the rate of false-positive findings based on the inclusion
of control patients and was chosen to minimize bias dur-
ing the diagnostic readout [11]. In a randomized and
blinded fashion, PET and CT were independently ana-
lyzed by two readers, one board-certified in radiology
and diagnostic nuclear medicine with 10 years of experi-
ence in hybrid imaging (C.C.C.) and one board-certified
in nuclear medicine with 15 years of experience in hy-
brid imaging (A.R.). Interreader agreement was assessed
using Cohen’s κ.
Statistical analysis
We performed all statistical analyses using SPSS Statis-
tics 23 (IBM; Armonk, NY, USA). For the comparison of
categorical variables, the Fisher’s exact test was used.
Categorical variables are presented as frequency and per-
centage. All metric and normally distributed variables
are reported as mean ± standard deviation; non-normally
distributed variables are presented as median (interquar-
tile range, IQR). The Mann-Whitney U test was applied
for numeric variables. Normal distribution was assessed
using the Kolmogorov-Smirnov test. P-values below 0.05
were considered to indicate statistical significance.
Results
Patient characteristics
The prevalence of myocardial lesions on 68Ga-DOTATA
TE PET in relation to the overall patient registry was
2.4%. 15 out of 629 NET patients (age: 65 ± 9; male sex:
60%) with a total number of 21 focal myocardial
68Ga-DOTATATE tracer uptakes fulfilled the inclusion
criteria. All focal myocardial uptakes detected were repro-
ducible in follow-up PET exams. There was excellent
agreement between the two readers (Cohen’s κ = 1.0). In
NET patients with myocardial lesions, the primary tumor
was most frequently located in the small intestine (73%).
Regarding initial disease stage, distant metastases were fre-
quently observed (73%). Compared to the overall NET
registry of our comprehensive cancer center, there were
no significant differences of patients with myocardial me-
tastases in patient age, patient sex, tumor grading, initial
disease stage, or initial levels of NET tumor markers (all
p > 0.05). Yet, patients with myocardial metastases demon-
strated higher expression of the proliferation marker
Ki67-Index compared to the overall registry (p = 0.049).
None of the patients with myocardial metastases suffered
from carcinoid heart disease. In one patient, the myocar-
dial metastasis was operatively resected due to its size with
histopathological results consistent with a NET metastasis.
The patient characteristics at the initial disease stage are
shown in Table 1.
Detection of myocardial PET lesions by conventional
imaging
CT reading showed a sensitivity of 19% (95% confidence
interval: 6–43%) at a specificity of 100% (95% confidence
interval: 90–100%) for the detection of myocardial lesions.
The diagnostic accuracy measures are shown in Table 2.
Liver MRI was part of the complementary NET staging in
14 subjects. Despite the partial field of view and incom-
plete scanning of the heart, five out of fourteen lesions
could be detected with liver MRI. Patient examples are
shown in Figs. 1, 2 and 3.
Characteristics and conventional imaging appearance of
myocardial PET lesions
Myocardial lesions were already detected at initial staging
in five patients (33% of study population). In the
remaining patients, myocardial lesions were identified a
median of six years after the initial diagnosis. The median
myocardial lesion SUVmax was 8.6 (relative to the physio-
logic spleen uptake: 0.386), the median myocardial lesion
SUVmean was 4.3 (relative to the physiologic spleen up-
take: 0.225). The lesions were most frequently located in
the left ventricle (43%) and the septum (43%), no lesions
were located in the left or right atrium. If evident, the
myocardial lesions most frequently appeared isodense on
CT, hyperintense on T2-weighted MR images and isoin-
tense on non-enhanced as well as contrast-enhanced
T1-weighted MR images. None of the patients demon-
strated a pericardial effusion. The characteristics are
shown in Table 3.
Discussion
Myocardial metastases detected by the PET component
of 68Ga-DOTATATE PET-CT were present in 2.4% of
NET patients in our comprehensive cancer center regis-
try. The sensitivity of conventional CT imaging was very
low within our study population while yielding very high
specificity. None of the patients demonstrated a pericar-
dial effusion, which might have indicated a cardiac
spread of the disease. Aside from higher values of the
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histological proliferation marker Ki67-Index in patients
with myocardial metastases compared to the overall
registry, no significant differences in patient characteris-
tics were detected. The frequency of myocardial metas-
tases in our patient cohort, the location of metastases,
and the time from initial NET diagnosis to diagnosis of
myocardial metastasis are in line with previous echocar-
diographic studies [12–14], with one study also investi-
gating cardiac MRI [14]. The results of our study
demonstrate that patients with myocardial metastases
from NET had very similar clinical, histological and
serological parameters during the initial tumor evalu-
ation. In particular, the tumor grading and the disease
stage showed no difference. In line with Calissendorff et
al. we also observed myocardial metastases in patients
without hepatic metastases [15].
The first reports on myocardial metastases in NET pa-
tients based on somatostatin receptor scintigraphy date
back to 1996 [16]. Soon after the introduction of
68Ga-DOTATATE PET imaging, reports followed on the
detection of focal myocardial uptakes consistent with me-
tastasis [17–19]. We extend the evidence on the diagnos-
tic value of 68Ga-DOTATATE PET by reporting the
interreader agreement for myocardial metastasis detec-
tion, which was excellent in our study, further supporting
68Ga-DOTATATE PET as a very accurate and robust
technique in staging well-differentiated NET. Additionally,
we provide data on the repeated detection of the focal
myocardial tracer uptakes, which were evident for every
myocardial lesion in every follow-up PET exam analyzed.
Besides 68Ga-DOTATATE, studies also investigated
18-Fluoro-dihydroxyphenylalanin (18F-DOPA) for the de-
tection of myocardial metastases [20, 21], demonstrating
the value of functional imaging in the detection of myo-
cardial lesions.
Regarding diagnostic accuracy, we report the low sen-
sitivities of CT imaging for myocardial metastasis detec-
tion as evaluated by expert reading of a case-control
cohort. We characterized the imaging appearance in
contrast-enhanced CT, and in MR imaging of the liver
whenever the lesions were depicted and evident. In CT,
only the mass effect contributed to the diagnosis as all
metastases appeared isodense to the surrounding myo-
cardium. For liver MR imaging, which is often per-
formed as a complementary diagnostic exam in NET
patients, T2-weighted sequences were occasionally useful
for incidental detection of myocardial metastases. This
further supports the use of 68Ga-DOTATATE PET in
the staging of NET patients, which has been shown to
be superior compared to morphologic imaging in the
Table 1 Characteristics of NET patients with myocardial lesions







Age (yrs) 65 (± 9) 63 (± 14) 0.915
Male sex 9/15 (60%) 333/616 (54%) 0.795
Location of primary tumor
Jejunum/Ileum 11/15 (73%) 182/387 (47%) N/A
Appendix 1/15 (6.7%) 18/387 (4.6%)
Colon 2/15 (13%) 27/387 (7.0%)
Undetermined 1/15 (6.7%) 15/387 (3.9%)
Tumor grading
G1 5/10 (50%) 126/255 (49%) 0.353
G2 3/10 (30%) 109/255 (43%)
G3 2/10 (20%) 20/255 (8%)
Ki67-Index
≤ 2% 5/12 (42%) 131/292 (45%) 0.049b
> 2–20% 4/12 (33%) 142/292 (49%)
> 20% 3/12 (25%) 19/292 (7%)
Disease stage
Localized 2/15 (13%) 44/227 (19%) 0.743
Regional metastasis 11/15 (73%) N/A N/A
Regional metastasis
only
2/15 (13%) 21/162 (13%) 1.000
Distant metastasis 11/15 (73%) 113/162 (70%) 1.000
Hepatic 6/11 (55%) N/A N/A
Peritoneal 4/11 (36%) N/A N/A
Osseous 6/11 (55%) N/A N/A
Myocardial 5/11 (45%) N/A N/A
Other 2/11 (18%) N/A N/A
Chromogranin A (ng/mL) 175 (95–9578) N/A N/A
Elevated Chromogranin A 7/10 (70%) 178/312 (57%) 0.526
5-HIAA urine secretion
(mg/24 h)
26 (10–80) N/A N/A
Elevated 5-HIAA urine
secretion
4/6 (66%) 178/312 (57%) 0.701
Carcinoid heart disease 0/15 (0%) N/A N/A
Values presented are count/available values (percentage) for categorical, mean
and standard deviation or median (interquartile range) for continuous
variables. Cut-off values for elevated Chromogranin A and 24-h 5-HIAA urine
secretion were 98 ng/mL and 9 mg/24 h respectively. 5-HIAA, 5-
hydroxyindoleacetic acid; N/A, not available
a Data are taken from the registry on neuroendocrine tumors (NET) of the
comprehensive cancer center (CCC). bStatistical test indicates significant
differences between groups
Table 2 Diagnostic accuracy of contrast-enhanced CT for
myocardial lesions detected on 68Ga-DOTATATE PET in NET
patients
Sensitivity Specificity PPV NPV
All lesions (N = 21)
CT 19 (6–43) 100 (90–100) 100 (40–100) 73 (60–93)
Values presented are percentages with the 95% confidence interval in
parentheses. PPV, positive predictive value; NPV, negative predictive value
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detection of the primary, the lymphatic as well as the
hematogenic spread of the disease [5]. Most import-
antly, 68Ga-DOTATATE PET significantly impacts
therapeutic management in more than 50% of NET pa-
tients, including initiation or continuance of peptide re-
ceptor radionuclide therapy, medical treatment or referral
to surgery. This is primarily driven by improved detection
of the primary tumor site or nodal, hepatic and peritoneal
metastases [8, 9]. It remains to be determined if the en-
hanced detection of myocardial metastases impacts pa-
tient management.
Carcinoid heart disease (CHD) is a frequent manifest-
ation in NET patients with carcinoid syndrome that has
been identified decades earlier than myocardial metastases
[22]. CHD significantly contributes to morbidity and mor-
tality of NET patients [13]. It likely results from high levels
of circulating vasoactive substances such as serotonin and
is characterized by plaque-like, fibrous endocardial thick-
ening involving in particular the right-sided heart valves.
This leads to valvular dysfunction and right-sided heart
failure. The management of CHD has improved over time,
and its prevalence decreased as a consequence of the use
of somatostatin analogues [23]. However, 68Ga-DOTATA
TE PET appears to have no value in the diagnosis of CHD,
which is based on echocardiography and circulating bio-
markers [23].
Yet, identifying myocardial metastasis may have clinical
implications based on the early reported significant over-
lap with carcinoid heart disease [12]. However, in our
study population, none of the patients suffered from car-
cinoid heart disease at the time that the myocardial lesions
were detected, which is in line with a recent report [20].
In accordance with this observation, we detected no dif-
ference in circulating tumor markers Chromogranin A or
5-hydroxyindoleacetic acid (5-HIAA) urine secretion, pos-
sible biomarkers for CHD [23], between patients with
myocardial metastases compared to the overall registry.
This further provides support to the hypothesis that CHD
and myocardial metastases are truly distinct pathologies.
There are limitations to this study that need to be con-
sidered when interpreting the results. First, histopatho-
logical validation of the focal myocardial 68Ga-DOTATA
Fig. 1 Patient example with a myocardial metastasis located at the apex evident on 68Ga-DOTATATE PET (a) and CT (b). A 77-year-old male
patient with a G3 neuroendocrine tumor of unknown origin with a myocardial metastasis to the apex of the heart. Strong 68Ga-DOTATATE tracer
uptake (a) correlates to the morphologic mass detected on CT imaging (b)
Fig. 2 Patient example with a myocardial metastasis detected using 68Ga-DOTATATE PET (a) without evidence on CT (b). In a 74-year-old female
patient with a G2 neuroendocrine tumor of the small intestine, 68Ga-DOTATATE PET (a) demonstrates strong focal uptake in the interventricular
septum without a morphologic correlate on CT imaging (b). This uptake was observed throughout all follow-up examinations consistent with a
myocardial metastasis
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TE uptake was not available as the risks conferred by
myocardial biopsies outweigh the diagnostic yield in the
context of metastatic NET patient management. However,
repeated focal myocardial PET tracer uptakes are consist-
ent with myocardial metastases. Second, our study popu-
lation had a limited number of patients, reflecting the
comparatively low prevalence of myocardial metastases in
NET patients.
Conclusions
68Ga-DOTATATE PET imaging provides added diag-
nostic value compared to morphologic CT imaging in
the detection as well as in the follow-up of myocardial
metastases in NET patients. Further studies are needed
to determine the impact on patient management.
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Fig. 3 Appearance of a myocardial metastasis on liver MRI performed as part of the complementary staging of the NET disease. A 72-year-old
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Table 3 Characteristics of myocardial lesions on 68Ga-DOTATA
TE PET in NET patients
Patients (n = 15) with
myocardial lesions (n = 21)
Myocardial lesion at baseline 5 (45%)
Time from initial diagnosis to lesion
appearance (yrs)
6 (2–10)
Patients with multiple lesions 3 (20%)
Patients with pericardial effusion 0 (0%)
Location
Left atrial 0 (0%)
Left ventricular 9 (43%)
Septal 9 (43%)
Right atrial 0 (0%)
Right ventricular 3 (14%)
Lesion SUVmax 8.6 (5.2–17.4)
Lesion SUVmean 4.3 (3.7–11.6)
Spleen SUVmax 22.3 (16.4–27.2)
Spleen SUVmean 19.1 (14.7–25.8)
Lesion appearance on CT imaginga
hyper−/ iso−/ hypodense 0 / 3 / 1
Lesion appearance on liver MR imaginga
T2w-hyper- / iso- / hypointense 5 / 0 / 0
T1w-hyper- / iso- / hypointense 0 / 3 / 0
CE-T1w-hyper- / iso- / hypointense 0 / 4 / 0
Values presented are count (percentage) for categorical and median (interquartile
range) for continuous variables. SUV, standardized uptake value; T2w, T2-
weighted; T1w, T1-weighted; CE-T1w; contrast-enhanced T1-weighted
a If evident on conventional imaging. Liver MRI was only available in 14 subjects
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